Never miss an update from AMAG Pharmaceuticals. Did you know that during reporting season, the announcements from NASDAQ:AMAG often move the market?
|52w High/Low:||$6.81 - 15.99|
|Volume/Average:||544K - 889K|
The drugmaker's Q3 results didn't matter very much in light of the prospect that it might have to yank Makena from the market.Q3 2019 Earnings Call Transcript
Q3 2019 Earnings Call TranscriptWhy AMAG Pharmaceuticals Is Tanking Today
Shares tumble after an FDA advisory committee recommends pulling one of the company's key drugs from the market. Here are the must-know details.Why AMAG Pharmaceuticals Stock Jumped Today
It continues to enjoy a strong rebound after a sell-off last week that investors seem to think was overdone.What's Behind AMAG Pharmaceuticals' Horrible Q2 Results
The drugmaker exited a key market, causing its top and bottom lines to tank in the second quarter.Q2 2019 Earnings Call Transcript
Q2 2019 Earnings Call TranscriptWhy Palatin Technologies Stock Dropped as Much as 21.5% Today
A high-profile analyst questioned the company's recent FDA approval.3 Drug Stocks That Could Win From Key FDA Approvals in June
Two hope to pick up additional indications for existing blockbuster drugs, while another could score a big victory for a new drug.